A matrix approach to guide IHC‐based tissue biomarker development in oncology drug discovery
- 10 December 2013
- journal article
- review article
- Published by Wiley in The Journal of Pathology
- Vol. 232 (2), 190-198
- https://doi.org/10.1002/path.4262
Abstract
Immunohistochemistry (IHC) is a core platform for the analysis of tissue samples, and there is an increasing demand for reliable and quantitative IHC‐based tissue biomarkers in oncology clinical research and development (R&D) environments. Biomarker assay and drug development proceed in parallel. Furthermore, biomarker assay requirements change with each phase of drug development. We have therefore developed a matrix tool to enable researchers to evaluate whether a particular IHC biomarker assay is fit for purpose. Experience gained from the development of 130 IHC biomarkers, supporting a large number of oncology drug projects, was used to formulate a practical approach to IHC assay development. The resultant matrix grid and accompanying work flow incorporates 16 core decision points that link antibody and assay specificity and sensitivity, and assay performance in preclinical and clinical samples, with stages of drug development. The matrix provides a means to ensure that relevant information on an IHC assay in development is recorded and communicated consistently and that minimum assay validation requirements are met. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 12 references indexed in Scilit:
- Companion Biomarkers: Paving the Pathway to Personalized Treatment for CancerClinical Chemistry, 2013
- Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicineEPMA Journal, 2013
- Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASCurrent Oncology, 2012
- The Use of Immunohistochemistry for Biomarker Assessment—Can It Compete with Other Technologies?Toxicologic Pathology, 2011
- Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid CancersClinical Cancer Research, 2010
- Antibody validationBioTechniques, 2010
- Biomarker-Driven Early Clinical Trials in OncologyThe Cancer Journal, 2009
- Biomarkers in oncology drug developmentMolecular Oncology, 2008
- Biomarker method validation in anticancer drug developmentBritish Journal of Pharmacology, 2008
- Phosphorylation State-Specific AntibodiesThe American Journal of Pathology, 2003